0001209191-17-059632.txt : 20171107
0001209191-17-059632.hdr.sgml : 20171107
20171107171129
ACCESSION NUMBER: 0001209191-17-059632
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171107
FILED AS OF DATE: 20171107
DATE AS OF CHANGE: 20171107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thistle Mary
CENTRAL INDEX KEY: 0001317917
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37601
FILM NUMBER: 171184334
MAIL ADDRESS:
STREET 1: C/O VIACELL, INC.
STREET 2: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dimension Therapeutics, Inc.
CENTRAL INDEX KEY: 0001592288
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463942159
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-401-0011
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-07
1
0001592288
Dimension Therapeutics, Inc.
DMTX
0001317917
Thistle Mary
C/O DIMENSION THERAPEUTICS, INC.
840 MEMORIAL DRIVE, 4TH FLOOR
CAMBRIDGE
MA
02139
0
1
0
0
Chief Operating Officer
Stock Option (Right to Buy)
3.57
2017-11-07
4
D
0
27711
D
2025-04-28
Common Stock
27711
0
D
Stock Option (Right to Buy)
3.57
2017-11-07
4
D
0
180815
D
2025-04-28
Common Stock
180815
0
D
Stock Option (Right to Buy)
4.09
2017-11-07
4
D
0
17104
D
2025-06-02
Common Stock
17104
0
D
Stock Option (Right to Buy)
7.14
2017-11-07
4
D
0
65000
D
2026-01-31
Common Stock
65000
0
D
Stock Option (Right to Buy)
1.90
2017-11-07
4
D
0
60000
D
2027-01-31
Common Stock
60000
0
D
This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This stock option, which vested 2,494 shares on February 2, 2016, and vests in 41 equal monthly installments thereafter, beginning February 3, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
/s/ Mary Thistle
2017-11-07